Looking into the Gene / Cell Therapy trial landscape

At LucidQuest (www.lqventures.com) we spend quite a bit of time conducting research in the Gene and Cell therapy space, focusing on better understanding the next key players and developments. 

Below you can find  a link to a small sample of a recent analysis, looking into the Gene / Cell Therapy trial landscape. For this part of our research we have included Phase II/III and Phase III trials with a listed (as found on clinicaltrials.gov database) primary endpoint completion in 2015-2019. Some of these trials have completed recruitment, others are yet to initiate patient enrolment; the majority are ongoing.

Gene / Cell Therapy trials

Some points to note

• >5,500 pts are being enrolled in these late stage Gene / Cell therapy studies run by a total of 18 companies (bluebird bio, Sarepta, Jazz Pharmaceuticals, Spark Therapeutics, Gensight and Viromed amongst them)
• Interesting mix of diseases under investigation (Crohn's, DMD, HF, melanoma, various cancers, retinal diseases etc.)
• Both viral (AAV, adeno), non-viral (plasmid, RNAi) and cell therapies (autologous, allogeneic) are being used
• Five studies expected to complete primary endpoint in 2016, four in 2017. nine in 2018 and 2 in 2019 (all dates as currently listed on clinicaltrials.gov website)

If you would like to gain more insights around these trials or in the Gene and Cell Therapy space in general, please contact us at [email protected]. 

You can find more about LucidQuest at www.lqventures.com or by following our LinkedIn page